Skip to content

Glatiramer prevents BBB Dysfunction in Mouse Multiple Sclerosis Model

October 5, 2013

Glatiramer is a random polymer of the four myelin basic protein constituent amino acids of glutamic acid, lysine, alanine, and tyrosine.  It is a drug approved for the treatment of relapsing multiple sclerosis, and is marketed by Teva Pharmaceticals as Copaxone. This company sponsored an Israeli study of the effect of glatiramer on the mouse blood brain barrier with results presented on October 4, 2013 at the Congress of the European Committee for the Treatment and Research in Multiple Sclerosis in Copenhagen, Denmark.  The investigators not only showed that glatiramer reduced BBB dysfunction with decreased neurovascular damage, but also showed the central role of BBB disruption in experimental encephalitis, a mouse model for multiple sclerosis.   

A link to the abstract is found here:

From → Posts

Leave a Comment

Leave a Reply